Visualization of growth in the COVID-19 impacted quarters

The first and second quarter of 2020 were unusual in many ways. More than a third of S&P500 companies temporarily or permanently withdrew guidance for the full year due to uncertainty surrounding impacts from COVID-19 according to FactSet. This article seeks to visualize the growth in each of the two quarters by sector and industry. […]

Best selling and fastest growing drugs in the 2nd quarter of 2020

Best selling drugs Once more Humira® from AbbVie is the best selling drug of the quarter ($4,837M) despite headwinds in Europe from biosimilars Amgevita®, Amsparity®, Halimatoz®, Hefiya®, Hulio®, Hyrimoz®, Idacio® and Imraldi®. In the US Humira® will in 2023 lose market exclusivity to the biosimilars Amjevita®, Cyltezo®, Hyrimoz®, Hadlima®, Abrilada® and Hulio®. AbbVie upon acquisition […]

Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus®

Novo Nordisk has reported their 2nd quarter results. Financials For the 2nd quarter sales were DKKm 30,006 (-0%), gross profit was DKKm 25,234 and operating income was DKKm 13,838 (+3%). In the US GLP1 for diabetes increased by 19%, whereas insulin decreased by 34%. CEO Lars Fruergaard Jørgensen “The U.S. sales decline was driven by […]